Board Meeting25 Sept 2026, 06:20 pm
Concord Drugs Closes Trading Window for Q2 FY27 Results
AI Summary
Concord Drugs Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the declaration of its un-audited financial results for the quarter and year ending September 30, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. During this period, directors, designated employees, and their immediate relatives are prohibited from trading in the company's securities. The exact date of the board meeting to consider these results will be communicated separately.
Key Highlights
- Trading window closed for Q2 FY27 financial results.
- Closure effective from October 1, 2026.
- Prohibits insider trading during the specified period.
- Applies to directors, designated employees, and relatives.
- Window reopens 48 hours post-results announcement.
Price Impact
More from CONCORD